Tumor Necrosis Factor Receptor Superfamily Member 9 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)- Pipeline Review, H2 2019’, provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)

– The report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AbClon Inc

ABL Bio Inc

Adagene (Suzhou) Ltd

Agenus Inc

Alligator Bioscience AB

Apogenix AG

Aptevo Therapeutics Inc

Avacta Life Sciences Ltd

Bicycle Therapeutics Plc

BioNTech SE

Bristol-Myers Squibb Co

Clover Biopharmaceuticals

Compass Therapeutics LLC

Crescendo Biologics Ltd

Eutilex Co Ltd

F. Hoffmann-La Roche Ltd

FasCure Therapeutics LLC

Hutchison MediPharma Ltd

I-Mab Biopharma Co Ltd

Inhibrx Inc

Juno Therapeutics Inc

KAHR medical Ltd

LeadArtis SL

Leads Biolabs Inc

Lyvgen Biopharma Ltd

MacroGenics Inc

Merus NV

Molecular Partners AG

Numab Innovation AG

Pfizer Inc

Pieris Pharmaceuticals Inc

Rubius Therapeutics Inc

Torque Therapeutics Inc

Xcella Biosciences Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Companies Involved in Therapeutics Development

Agenus Inc

Alligator Bioscience AB

Apogenix AG

Bicycle Therapeutics Ltd

BioInvent International AB

BioNTech AG

Bristol-Myers Squibb Co

Crescendo Biologics Ltd

F. Hoffmann-La Roche Ltd

Inhibrx LP

Juno Therapeutics Inc

KAHR medical Ltd

LeadArtis SL

MacroGenics Inc

Molecular Partners AG

Numab Innovation AG

Pieris Pharmaceuticals Inc

Rubius Therapeutics Inc

Torque Therapeutics Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drug Profiles

ABP-300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADG-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGEN-2373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALG.APV-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aptamer to Antagonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATOR-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target HER2 and CD137 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target EphA2 and CD137 for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target CD137L for Nasopharyngeal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EU-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EU-900 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize CD137 for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Target CEA and 4-1BB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INBRX-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISAS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lisocabtagene maraleucel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize 41BB for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target CD137 and IL2R for Metastatic Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OrthomAb - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRS-343 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-7827 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTX-41BBL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCB-333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize CD137 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ultra-41BBL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

urelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Product Development Milestones

Featured News & Press Releases

Sep 28, 2018: New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017

Sep 20, 2018: Numab appoints immunotherapy pioneer Ignacio Melero as scientific advisor

Sep 04, 2018: Pieris Pharmaceuticals announces dosing of first patient in phase I combination trial for PRS-343 plus anti-PD-L1 immunotherapy

Jul 09, 2018: US FDA Approves Adagene IO Agonist IND for Solid Tumor and Non-Hodgkin Lympoma Ph1 Trial

Jun 21, 2018: Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells

Jun 03, 2018: Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO

May 16, 2018: Celgene to Present Results from JCAR017 at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions

May 08, 2018: New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics

May 03, 2018: Alligator Bioscience: ATOR-1017 Pre-clinical Data Support a Best-in-class 4-1BB Antibody Profile

Apr 05, 2018: Molecular Partners to present MP0310 pre-clinical data at the AACR Annual Meeting 2018

Dec 12, 2017: Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

Dec 11, 2017: Juno Therapeutics and Celgene Corporation Release Additional Data from TRANSCEND Trial of JCAR017 in Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Dec 09, 2017: Juno Therapeutics Highlights Key Translational Insights with JCAR017 in Patients with DLBCL

Nov 09, 2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology

Nov 01, 2017: Juno Therapeutics to Showcase Promising Data from JCAR-017 Product Development Program at ASH Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbClon Inc, H2 2019

Pipeline by ABL Bio Inc, H2 2019

Pipeline by Adagene (Suzhou) Ltd, H2 2019

Pipeline by Agenus Inc, H2 2019

Pipeline by Alligator Bioscience AB, H2 2019

Pipeline by Apogenix AG, H2 2019

Pipeline by Aptevo Therapeutics Inc, H2 2019

Pipeline by Avacta Life Sciences Ltd, H2 2019

Pipeline by Bicycle Therapeutics Plc, H2 2019

Pipeline by BioNTech SE, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Clover Biopharmaceuticals, H2 2019

Pipeline by Compass Therapeutics LLC, H2 2019

Pipeline by Crescendo Biologics Ltd, H2 2019

Pipeline by Eutilex Co Ltd, H2 2019

Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Pipeline by FasCure Therapeutics LLC, H2 2019

Pipeline by Hutchison MediPharma Ltd, H2 2019

Pipeline by I-Mab Biopharma Co Ltd, H2 2019

Pipeline by Inhibrx Inc, H2 2019

Pipeline by Juno Therapeutics Inc, H2 2019

Pipeline by KAHR medical Ltd, H2 2019

Pipeline by LeadArtis SL, H2 2019

Pipeline by Leads Biolabs Inc, H2 2019

Pipeline by Lyvgen Biopharma Ltd, H2 2019

Pipeline by MacroGenics Inc, H2 2019

Pipeline by Merus NV, H2 2019

Pipeline by Molecular Partners AG, H2 2019

Pipeline by Numab Innovation AG, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Pieris Pharmaceuticals Inc, H2 2019

Pipeline by Rubius Therapeutics Inc, H2 2019

Pipeline by Torque Therapeutics Inc, H2 2019

Pipeline by Xcella Biosciences Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports